HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

paquinimod

Also Known As:

ABR-215757

Networked: 30 relevant articles (7 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - paquinimod: 30

Experts

1.	Leanderson, Tomas: 8 articles (01/2018 - 08/2010)
2.	Ivars, Fredrik: 6 articles (01/2018 - 08/2010)
3.	Sparre, Birgitta: 3 articles (01/2021 - 05/2012)
4.	Tuvesson, Helén: 3 articles (01/2021 - 05/2012)
5.	Törngren, Marie: 3 articles (01/2021 - 07/2016)
6.	Deronic, Adnan: 3 articles (01/2018 - 05/2013)
7.	Stenström, Martin: 3 articles (07/2016 - 08/2010)
8.	Helmersson, Sofia: 3 articles (02/2014 - 08/2011)
9.	Baek, Dong Gyu: 2 articles (01/2021 - 01/2021)
10.	Chang, Hun Soo: 2 articles (01/2021 - 01/2021)

Related Diseases

1.	Autoimmune Diseases (Autoimmune Disease) 08/01/2011 - "Carboxamides such as ABR-215757 (5757) have shown efficacy in several in vivo mouse models of human inflammatory autoimmune disease. " 11/01/2016 - "Quinoline-3-carboximide compounds, such as paquinimod, which targets the protein S100A9, have demonstrated efficacy in treating autoimmune diseases. " 08/01/2010 - "The quinoline-3-carboxamide ABR-215757 (5757) is in clinical development for the treatment of human SLE and has shown efficacy in several mouse models of T cell-mediated inflammatory autoimmune disease. " 11/01/2020 - "Laquinimod and paquinimod show promising results in the treatment of autoimmune diseases, tasquinimod is considered primarily as an anti-cancer drug. "
2.	Atherosclerosis 05/01/2013 - "Our data suggest that S100A12 is important for progression of atherosclerosis and can be targeted by the small molecule ABR-215757. " 05/01/2013 - "In this study we tested the efficacy of ABR-215757, a S100 protein binding immuno-modulatory compound to stabilize atherosclerosis in transgenic ApoE null mice that express the human pro-inflammatory S100A12 protein within the smooth muscle cell (SM22α-S100A12). "
3.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/01/2012 - "To assess the efficacy of paquinimod, a new immunomodulatory small molecule, in a murine lupus model, and to evaluate its pharmacokinetics and tolerability in systemic lupus erythematosus (SLE) patients at doses predicted to be efficacious and safe and determine the maximum tolerated dose. " 05/01/2012 - "Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus."
4.	Glomerulonephritis 11/01/2016 - "The aim of this study was to assess the efficacy of paquinimod in the prevention and treatment of experimental glomerulonephritis. "
5.	Sepsis (Septicemia) 01/01/2022 - "Both pharmacological inhibition using Paquinimod and genetic ablation of the S100A8/A9-TLR4 signaling axis improved survival in mice with CLP-induced sepsis by suppressing platelet pyroptosis." 01/01/2023 - "Moreover, we found that S100A9+ monocytes exhibited profound immunosuppressive function on CD4+ T cell immune response and blockade of S100A9 using Paquinimod could partially reverse sepsis-induced immunosuppression. "

Related Drugs and Biologics

1.	quinoline-3-carboxamide
2.	S100 Proteins (S 100 Protein)
3.	Apolipoproteins E (ApoE)
4.	S100A12 Protein
5.	Proteins (Proteins, Gene)
6.	tasquinimod
7.	laquinimod
8.	Biomarkers (Surrogate Marker)
9.	Ovalbumin
10.	Freund's Adjuvant

Related Therapies and Procedures

1.	Therapeutics
2.	Punctures
3.	Nephrectomy
4.	Ligation